Respiratory Disorders: Mapping the Future Potential

The World Health Organization (WHO) estimates the global prevalence of two of the most common chronic respiratory disorders, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. According to the data provided by the WHO, more than 3 million people die annually from COPD. Asthma, on the other hand, is more common in pediatric population. Asthma alone results in more than 30% of pediatric hospitalizations. Moreover, it is responsible for around 180,000 annual deaths worldwide.

Respiratory Disorders are Amongst the Most Prevalent Global Diseases

Evaluation of opinions expressed across social media platforms, recent publications and by KOLs highlights significant unmet needs across these diseases.

Current Research Initiatives are Focused on a Number of Unmet Needs

To overcome these unmet needs, stakeholders must focus on development of therapies / solutions to address issues related to medication adherence and disease diagnosis.

Novel Targets are Being Explored Across Asthma, COPD and Cystic Fibrosis

Innovation in this segment is presently concentrated on exploring unique targets and developing personalized therapies for patients with moderate to severe form of disease

As per Roots Analysis, around 40% of the novel drug candidates are used for asthma.

Both Big and Small Pharma are Actively Driving the Research Efforts in the Respiratory Disorders Market

The efforts are being jointly led by large and small-mid size pharma companies aiming to occupy a relatively larger share of this highly lucrative market

Many Companies, with Compelling Brand Positioning, Have Recently Emerged

Specific companies, which are developing novel solutions and have a relatively stronger brand positioning, are expected to transform the treatment options in the mid-long term

Smart Inhalers Are Also Gaining Rapid Popularity

With the growing traction towards digital solutions to overcome specific patient needs, smart inhalers are also likely to offer significant opportunities

Majority of developers based in North America are offering smart inhalers- Roots Analysis

The Overall Opportunity for Novel Drug Classes is Expected to Steadily Grow

Driven by encouraging clinical trial results and increasing adoption of these novel therapies, the respiratory disorders market is poised to grow at a rapid pace

The Asthma, COPD and Cystic Fibrosis Market is fragmented across various segmentations including drug class, indications, key players and geography- Roots Analysis

To learn more, please click Respiratory Disorders Market. For any queries / suggestions, please do not hesitate to contact us at You can also download the SAMPLE REPORT on respiratory disorders by Roots Analysis. 

Our Social Media Platform